{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:33Z","timestamp":1791474693476,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.beha.2017.10.005","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T08:02:39Z","timestamp":1509523359000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Transformation of follicular lymphoma \u2013 Why does it happen and can it be prevented?"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian K.","family":"Link","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.beha.2017.10.005_bib1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2017.10.005_bib2","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","article-title":"Unmet needs in the first-line treatment of follicular lymphoma","volume":"28","author":"Casulo","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"23","key":"10.1016\/j.beha.2017.10.005_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lympho care study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2017.10.005_bib4","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.beha.2017.10.005_bib5","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.30795","article-title":"Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group","volume":"23","author":"Provencio","year":"2017","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.beha.2017.10.005_bib6","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3109\/10428194.2014.885513","article-title":"Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis","volume":"55","author":"Mozessohn","year":"2014","journal-title":"Leukemia Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2017.10.005_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-Alvarez","year":"2017","journal-title":"Br J Haematol"},{"issue":"32","key":"10.1016\/j.beha.2017.10.005_bib8","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.10.005_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2017.10.005_bib10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2017.10.005_bib11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gine","year":"2006","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"10.1016\/j.beha.2017.10.005_bib12","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1080\/10428194.2016.1265114","article-title":"Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003\u20132013","volume":"58","author":"Gleeson","year":"2017","journal-title":"Leukemia Lymphoma"},{"issue":"26","key":"10.1016\/j.beha.2017.10.005_bib13","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of Iowa\/MayoClinic specialized program of research excellence molecular epidemiology resource","volume":"31","author":"Link","year":"2013","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2017.10.005_bib14","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2017.10.005_bib15","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2017.10.005_bib16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.10.005_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"27","key":"10.1016\/j.beha.2017.10.005_bib18","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2017.10.005_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.beha.2011.02.006","article-title":"Transformation of follicular lymphoma","volume":"24","author":"Lossos","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"10.1016\/j.beha.2017.10.005_bib20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.V59.2.258.258","article-title":"Histologic progression in non-Hodgkin's lymphoma","volume":"59","author":"Hubbard","year":"1982","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2017.10.005_bib21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/1097-0142(19840301)53:5<1109::AID-CNCR2820530516>3.0.CO;2-O","article-title":"Malignant lymphomas of follicular center cell origin in humans. V. Incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma","volume":"53","author":"Oviatt","year":"1984","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2017.10.005_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/1097-0142(197709)40:3<959::AID-CNCR2820400302>3.0.CO;2-3","article-title":"Composite lymphoma","volume":"40","author":"Kim","year":"1977","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.beha.2017.10.005_bib23","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.3324\/haematol.2016.144550","article-title":"Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas","volume":"101","author":"Kansara","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2017.10.005_bib24","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP","volume":"29","author":"Sehn","year":"2011","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.10.005_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2017.10.005_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"21","key":"10.1016\/j.beha.2017.10.005_bib27","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2017.10.005_bib28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.humpath.2009.10.027","article-title":"B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology","volume":"41","author":"Carbone","year":"2010","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.beha.2017.10.005_bib29","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2009.008128","article-title":"Novel lymphoid neoplasms\u2013the borderland between diffuse large B-cell lymphoma and Burkitt's lymphoma","volume":"94","author":"de Jong","year":"2009","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.beha.2017.10.005_bib30","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2017.10.005_bib31","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM198805263182106","article-title":"Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma","volume":"318","author":"De Jong","year":"1988","journal-title":"N.\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2017.10.005_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00000478-200004000-00006","article-title":"Blastic\/blastoid transformation of follicular lymphoma: immunohistologic and molecular analyses of five cases","volume":"24","author":"Natkunam","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"18","key":"10.1016\/j.beha.2017.10.005_bib33","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.10.005_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/his.13316","article-title":"MYC expression and translocation analyses in low-grade and transformed Follicular Lymphoma","author":"Aukema","year":"2017","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.beha.2017.10.005_bib35","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2017.10.005_bib36","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","article-title":"p53 mutation is associated with progression in follicular lymphomas","volume":"82","author":"Sander","year":"1993","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2017.10.005_bib37","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood.V91.12.4677","article-title":"Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma","volume":"91","author":"Elenitoba-Johnson","year":"1998","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2017.10.005_bib38","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1073\/pnas.1137463100","article-title":"Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy","volume":"100","author":"Elenitoba-Johnson","year":"2003","journal-title":"Proc Natl Acad Sci U. S. A"},{"issue":"13","key":"10.1016\/j.beha.2017.10.005_bib39","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.1073\/pnas.132253599","article-title":"Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes","volume":"99","author":"Lossos","year":"2002","journal-title":"Proc Natl Acad Sci U. S. A"},{"issue":"7360","key":"10.1016\/j.beha.2017.10.005_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.beha.2017.10.005_bib41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.beha.2017.10.005_bib42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.beha.2017.10.005_bib43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms","volume":"136","author":"Davies","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2017.10.005_bib44","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2002-07-2119","article-title":"Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations","volume":"101","author":"Martinez-Climent","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2017.10.005_bib45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nrm3479","article-title":"Mitochondria: master regulators of danger signalling","volume":"13","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"10.1016\/j.beha.2017.10.005_bib46","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1172\/JCI200422269","article-title":"Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics","volume":"114","author":"Lee","year":"2004","journal-title":"J\u00a0Clin Investig"},{"issue":"3","key":"10.1016\/j.beha.2017.10.005_bib47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cmet.2011.07.010","article-title":"Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation","volume":"14","author":"Tucker","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.beha.2017.10.005_bib48","doi-asserted-by":"crossref","first-page":"e1152","DOI":"10.1038\/cddis.2014.112","article-title":"Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers","volume":"5","author":"Sheth","year":"2014","journal-title":"Cell Death Dis"},{"issue":"9","key":"10.1016\/j.beha.2017.10.005_bib49","doi-asserted-by":"crossref","first-page":"e0134833","DOI":"10.1371\/journal.pone.0134833","article-title":"High throughput sequencing analysis of the immunoglobulin heavy chain gene from flow-sorted B cell sub-populations define the dynamics of follicular lymphoma clonal evolution","volume":"10","author":"Carlotti","year":"2015","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.beha.2017.10.005_bib50","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.beha.2017.10.005_bib51","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"364","key":"10.1016\/j.beha.2017.10.005_bib52","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.beha.2017.10.005_bib53","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"10.1016\/j.beha.2017.10.005_bib54","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2017.10.005_bib55","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.18632\/oncotarget.14509","article-title":"Clonal evolution in therapy-related neoplasms","volume":"8","author":"Fabiani","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.beha.2017.10.005_bib56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.beha.2017.10.005_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"21","key":"10.1016\/j.beha.2017.10.005_bib58","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N.\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2017.10.005_bib59","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.10.005_bib60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.beha.2017.10.005_bib61","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.10.005_bib62","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma","volume":"25","author":"Glas","year":"2007","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2017.10.005_bib63","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.10.005_bib64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol"},{"issue":"224","key":"10.1016\/j.beha.2017.10.005_bib65","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.beha.2017.10.005_bib66","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.beha.2017.10.005_bib67","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.clinbiochem.2015.04.005","article-title":"The translational potential of circulating tumour DNA in oncology","volume":"48","author":"Patel","year":"2015","journal-title":"Clin Biochem"},{"issue":"24","key":"10.1016\/j.beha.2017.10.005_bib68","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2017.10.005_bib69","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.beha.2017.10.005_bib70","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","author":"Roschewski","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2017.10.005_bib71","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1158\/2326-6066.CIR-14-0110","article-title":"Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic","volume":"2","author":"Finn","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.beha.2017.10.005_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx030","article-title":"Annual report to the nation on the status of cancer, 1975\u20132014, featuring survival","volume":"109","author":"Jemal","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.beha.2017.10.005_bib73","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMp1604113","article-title":"Saving the World's women from cervical cancer","volume":"374","author":"Tsu","year":"2016","journal-title":"N.\u00a0Engl J Med"},{"issue":"9383","key":"10.1016\/j.beha.2017.10.005_bib74","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2017.10.005_bib75","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2 Suppl 2","key":"10.1016\/j.beha.2017.10.005_bib76","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.beha.2017.10.005_bib77","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.beha.2017.10.005_bib78","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.10.005_bib79","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.14688","article-title":"Risk of histological transformation and therapy-related myelodysplasia\/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma","volume":"178","author":"Epperla","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2017.10.005_bib80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.stem.2017.08.001","article-title":"Prostaglandin E1 and its analog misoprostol inhibit human CML stem cell self-renewal via EP4 receptor activation and repression of AP-1","volume":"21","author":"Li","year":"2017","journal-title":"Cell Stem Cell"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:01:26Z","timestamp":1603234886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1521692617300567"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transformation of follicular lymphoma \u2013 Why does it happen and can it be prevented?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}